| Literature DB >> 31597751 |
Salo N Ooft1,2, Fleur Weeber1,2, Krijn K Dijkstra1,2, Chelsea M McLean1,2, Sovann Kaing1,2, Erik van Werkhoven3, Luuk Schipper1,2, Louisa Hoes1,2, Daniel J Vis2,4, Joris van de Haar1,2,4, Warner Prevoo5, Petur Snaebjornsson6, Daphne van der Velden1,2, Michelle Klein1,2, Myriam Chalabi1, Henk Boot7, Monique van Leerdam7, Haiko J Bloemendal8, Laurens V Beerepoot9, Lodewyk Wessels2,4,10, Edwin Cuppen2,11,12, Hans Clevers2,13,14, Emile E Voest15,2,7.
Abstract
There is a clear and unmet clinical need for biomarkers to predict responsiveness to chemotherapy for cancer. We developed an in vitro test based on patient-derived tumor organoids (PDOs) from metastatic lesions to identify nonresponders to standard-of-care chemotherapy in colorectal cancer (CRC). In a prospective clinical study, we show the feasibility of generating and testing PDOs for evaluation of sensitivity to chemotherapy. Our PDO test predicted response of the biopsied lesion in more than 80% of patients treated with irinotecan-based therapies without misclassifying patients who would have benefited from treatment. This correlation was specific to irinotecan-based chemotherapy, however, and the PDOs failed to predict outcome for treatment with 5-fluorouracil plus oxaliplatin. Our data suggest that PDOs could be used to prevent cancer patients from undergoing ineffective irinotecan-based chemotherapy.Entities:
Year: 2019 PMID： 31597751 DOI： 10.1126/scitranslmed.aay2574
Source DB: PubMed Journal: Sci Transl Med ISSN： 1946-6234 Impact factor: 17.956